Examples of our work

---

This comprehensive review evaluates the safety of fetal MRI during pregnancy and finds strong evidence that non‑contrast MRI at both 1.5 T and 3 T is not associated with significant short‑ or long‑term adverse outcomes, while also offering meaningful diagnostic advantages over ultrasound in complex cases. Although data on first‑trimester exposure and gadolinium contrast remain limited, current evidence supports the cautious, selective use of MRI as a safe and valuable tool in prenatal care.

 A monograph on weight loss using semaglutide. Obesity is a chronic, multifactorial disease affecting over 40% of U.S. adults and significantly increasing the risk of cardiovascular disease, diabetes, and premature mortality, while imposing more than $170 billion annually in healthcare costs. Emerging evidence shows that semaglutide not only produces sustained weight loss of 12–15% but also reduces major cardiovascular events by 20%, reinforcing obesity as a chronic, treatable disease requiring comprehensive, long‑term management. 

 This presentation reviews semaglutide as an evidence‑based therapy for chronic weight management, detailing its GLP‑1 mechanism of action, clinical efficacy, indications, contraindications, and safety profile. It highlights semaglutide’s ability to achieve meaningful, sustained weight loss and reduce cardiovascular risk while emphasizing the importance of comprehensive, long‑term obesity management and patient-centered care.